Kiora Q2 net loss $2.6M; ABACUS phase 1b shows KIO-301 proof-of-concept in retinitis pigmentosa

KIORA PHARMACEUTICALS INC

2023-Q2 EPS reported -$1.74

Net loss $2.6M in Q2 2023 vs $2.4M Q2 2022; cash $8.0M at quarter end.
Preliminary ABACUS data: KIO-301 safe/tolerable with positive vision impact; topline results expected Q4 2023.
Sharpened focus on rare retinal diseases; KIO-301 trials to expand to choroideremia and Stargardt's disease.
Shifted resources from KIO-101 (ocular RA) to KIO-104 (posterior uveitis); seeking partnerships for anterior segment programs.
Raised $6.3M funding extending runway to May 2024; received $1.2M in R&D tax credits from Australia and Austria.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

KIORA PHARMACEUTICALS INC reported second quarter 2023 results: net income Net loss was $2.6 million for the second quarter of 2023.

Period: second quarter 2023
Net income: Net loss was $2.6 million for the second quarter of 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended June 30, 2023 and an update on clinical development progress.

View on SEC.gov

Browse all earnings releases →

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001372514-23-000118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.